The study aims to compare the methods of Mucosat drug use and administration for achieving the desired therapeutic effect in the treatment of osteoarthritis.
Despite extensive evidence base, improving complex therapy schemes for the use of successive and complementary dosage forms with the appropriate drug administration and use in order to achieve the desired therapeutic effect is still a valid aim.
In the course of the study, 50 knee osteoarthritis patients were examined and treated during the period from November, 2019 to April, 2020.
A clinical trial was carried out to assess Mucosat oral and parental administration effectiveness in the patients comparing their physical activity, functional ability and quality of life. The number of undesired side effects identified the degree of therapeutic tolerance against the comorbid diseases identified. A comparison of the therapeutic efficacy and tolerability of Musocat intramuscular and capsule administration, patient compliance, the need to take non-steroidal anti-inflammatory drugs (NSAIDs) was drawn.
Statistica 12 and Excel 2016 were used to carry out the statistical analysis of the data obtained. The study was generally marked by diagnostic accuracy with the use of modern methods, group homogeneity, prospective observational design.
By the time of pharmacotherapy completion, physical activity has become optimal in the study groups. However, parental therapy had significantly higher effectiveness than the oral one on all the subscales. As a result, articular syndrome severity has been reduced and the functional state of the joints expanded.
The study has shown that Mucosat demonstrates high efficacy both in injectable solution and capsule dosage forms as a basic chondroprotective drug. Mucosat pharmacotherapy course has contributed to permanent discontinuation of NSAIDs before completion of the therapy. The superiority of Mucosat parenteral administration over the oral one has been proven.
Comparison of the effectiveness of supplementary prescribing the chonodoprotector Mucosat in the oral and parenteral dosage forms during the acute exacerbation of osteoarthritis
